Mita, Alain C <br/><br/>
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jun 2010 
 - 3044-56 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-09-3368  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Angiopoietin-1--antagonists & inhibitors<br/>Angiopoietin-2--antagonists & inhibitors<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Drug Administration Schedule<br/>Drugs, Investigational--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Recombinant Fusion Proteins--adverse effects<br/>Recombinant Proteins--administration & dosage